Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05593614 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
A Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, sponsored by AlgoTherapeutix.
- Active
- Registry status
- Phase 2
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT05593614: Active Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, sponsored by AlgoTherapeutix.
NCT05593614 is a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by AlgoTherapeutix. The registered enrollment target is 276 participants, above the 129-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05593614, a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by AlgoTherapeutix.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ATX01 10%
- DRUG ATX01 15%
Study Locations (20)
Other
- OLV Hospital Aalst: gastro-enterologie - Aalst
- Universitair Ziekenhuis Antwerpen - Edegem
- Universitair Ziekenhuis Gent (UZ Gent) - Ghent
- UZ Leuven / Campus Pellenberg / Pain Center - Pellenberg
- CHU UCL Namur - site Godinne - Yvoir
- Clinitrial s.r.o. - Prague
- Praglandia s.r.o. - Prague
- Nemocnice Teplice - Teplice
- Centre Hospitalier de la Côte Basque - Bayonne
- Institute Bergonie - Bordeaux
- CHU de Montpellier, Hôpital Saint Eloi - Montpellier
- Groupe Hospitalier Paris Saint Joseph - Paris
Florida
- South Lake Pain Institute - Clermont
- MGM Medical Care Research & Rehab, LLC - Miami
- Medsol Clinical Research Center, Inc - Port Charlotte
- Knight Neurology - Clinical Research - Rockledge
Kansas
- Neuroscience Research Center, LLC. - Overland Park
Maryland
- The Center for Cancer and Blood Disorders (CCBD) - Bethesda
New York
- University of Rochester Medical Center - Rochester
Texas
- HD Research - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2024-09 |
| Phase | Phase 2 |
What the registry record for NCT05593614 still lists
NCT05593614 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, above the 129-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (114% higher).
The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05593614 names 20 study sites across 6 states, led by Other, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT05593614 about?
NCT05593614 is a clinical study titled "Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)". The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.
What is the current status of trial NCT05593614?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 276 participants. The study started on 2023-02-28. Estimated completion is 2024-09.
What conditions does trial NCT05593614 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT05593614?
The interventions under investigation include: Placebo (DRUG), ATX01 10% (DRUG), ATX01 15% (DRUG).
Who is sponsoring clinical trial NCT05593614?
This trial is sponsored by AlgoTherapeutix, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05593614 being conducted?
This trial has 20 study locations across Florida, Kansas, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05593614's enrollment target sits among peer trials
276 5th of 29 higher than 25 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
RECRUITING · Phase 2
-
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI